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n the past ten years, the rich 
world has begun to get serious 
about tackling the diseases that 
predominantly affect poor people, 
diseases that impose an enormous 
humanitarian and economic burden 
upon those least able to bear it. 
Infections comprise the majority of this 
burden, and three have been singled 
out for particular attention: HIV/AIDS, 
tuberculosis, and malaria. Of these, 
malaria is probably the easiest to attack. 
But how should we attack it?
    Strategies for Malaria Control
    Traditionally, we have relied on vector 
control (killing anopheline mosquitoes) 
and drug treatment of malaria episodes, 
and this combined approach has 
proved remarkably effective in many 
settings. Malaria is no longer a problem 
in most of China, Russia, Europe, and 
North America. But attempts at global 
eradication foundered in the tropics 
in the 1960s [1], and we have been 
reluctant to try again.
    Waiting for a malaria vaccine has 
provided one excuse for treading water, 
but whilst we have waited, malaria 
morbidity and mortality have worsened 
[2]. Resistance to the widely available 
and inexpensive chloroquine and 
sulphadoxine-pyrimethamine (SP) 
has been the main culprit [3]. Doing 
nothing is not an option. Fortunately, 
we do now have malaria control 
interventions that work: effective 
insecticides, insecticide-impregnated 
materials (particularly bed nets), 
and highly effective drugs. And there 
is increasing political will to direct 
international donor assistance to 
malaria control. 
    How Should Donor Funds Be 
Spent?
    So how should we use the increasing 
funds available for purchasing 
malaria control tools to best effect? In 
particular, how can we prevent or at 
least delay losing the new antimalarial 
drugs to resistance? If we are to roll 
back malaria, we will certainly need 
to deploy highly effective antimalarial 
drugs on a much wider scale than we 
do now.
    There are some areas of broad 
agreement, many of which apply 
more generally to infectious disease 
treatments. Inadequate dosing must 
be avoided, ﬁ  xed combinations of 
drugs (as used in the treatment of 
tuberculosis and HIV/AIDS) should 
become the norm, and unnecessary 
overuse should be minimised. When 
large numbers of malaria parasites are 
exposed to antimalarial drugs, then 
spontaneously arising mutants with 
point mutations or gene ampliﬁ  cations 
that confer reduced drug susceptibility 
may be selected. This selective pressure 
is inevitable when slowly eliminated 
drugs are deployed on a large scale in 
malaria-endemic areas. 
    Resistance has developed to 
all currently available classes of 
antimalarial drugs, with the important 
exception of the artemisinin 
compounds. Mass treatment and large-
scale prophylaxis with antimalarial 
drugs (mainly chloroquine, 
pyrimethamine, and piperaquine) has 
been associated with the emergence of 
resistance. Chemoprophylaxis is now 
recommended only for travellers and 
for women in pregnancy, although the 
only drugs considered safe enough 
for continuous use in pregnancy 
(chloroquine and proguanil) are now 
largely ineffective against falciparum 
malaria. 
  An  Alternative  Strategy: 
Intermittent Presumptive Therapy
    An alternative control strategy that 
has proved effective in reducing the 
adverse effects of malaria in pregnancy 
and infancy is to give full treatment 
doses at intervals [4]. This intermittent 
presumptive treatment (IPT) has 
been evaluated mainly in areas of high 
stable transmission, and mainly with 
SP (and mainly at a time when SP was 
a lot more effective than it is today). 
IPT currently involves administering 
treatment doses in the second and 
third trimesters of pregnancy, or 
together with routine childhood 
immunisations (the Expanded 
Programme of Immunisation) at two, 
three, and nine months of age. To 
date, IPT deployment is limited and is 
largely conﬁ  ned to SP or amodiaquine 
as monotherapies, but deployment 
is likely to increase considerably. 
However, such extensive deployment 
of antimalarials to healthy pregnant 
women and infants would provide a 
selection pressure to the emergence 
of drug resistance. It might jeopardise 
the valuable new drugs now being 
introduced as treatments. As we cannot 
measure selection pressure directly, 
and as a complex mix of interacting 
factors determine the epidemiology 
of malaria and antimalarial drug 
resistance, we must resort to predictive 
modelling as a guide to possible future 
outcomes. 
    Wendy Prudhomme O’Meara and 
colleagues provide us with such a 
modelling exercise in a new study 
in   PLoS Medicine   [5]. Their study 
is a comprehensive one, and it is 
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sophisticated by comparison with 
earlier modelling exercises in this 
ﬁ  eld. Their model incorporates 
immunity, transmission intensity, 
and pharmacokinetic properties of 
the drugs. Using a simpliﬁ  ed binary 
classiﬁ  cation of resistance, they predict 
that “partially resistant” parasites are 
more likely to arise in low-transmission 
areas, but “fully resistant” parasites 
are more likely to spread under 
conditions of high transmission. The 
model predicts that deployment of 
intermittent preventive treatment in 
infants could accelerate the spread of 
resistant parasites, but that this effect 
would be signiﬁ  cant only in areas of low 
or unstable transmission (where IPT 
has yet to be deployed). The authors 
recommend that drugs to which little 
or no resistance exists should not be 
used for IPT in high-transmission 
areas (otherwise, they might be lost 
prematurely), but that use of IPT in 
infants is not likely to affect the spread 
of highly resistant parasites signiﬁ  cantly 
in areas where partial resistance is 
already established. 
    Implications of the New Model
    Wendy Prudhomme O’Meara and 
colleagues’ conclusions are generally 
reassuring. But are they right? More 
importantly, should we act on the basis 
of these predictions? For example, 
should policymakers not deploy new 
antimalarial drugs, to which resistance 
has not yet developed (that is, assuming 
they are safe and effective), for IPT—as 
recommended by the authors?
    The problem with malaria 
models, even one as advanced 
and comprehensive as this new 
model, is that they are still a vast 
oversimpliﬁ  cation of a very complex 
system. The characterisations 
of immunity, population 
antimalarial pharmacokinetics 
and pharmacodynamics, and the 
epidemiology of malaria transmission 
in current models are all insufﬁ  cient. 
In addition, geographical, behavioural, 
and biological heterogeneities 
are not accounted for adequately. 
Modellers should be encouraged to 
describe clearly the limitations of 
their predictions (based on equations 
that most general readers studiously 
avoid attempting to digest). We really 
do not know whether the results of 
sensitivity analyses and the conclusions 
based on these simpliﬁ  cations can be 
extrapolated to the “real world”. In this 
particular case, we are not even very 
sure how IPT “works”.
    So we should treat the results of such 
well-conducted modelling exercises 
with caution, but we should not ignore 
them either, as they provide us with 
valuable direction in research and 
identify areas of potential concern. In 
this case, the new model provides an 
important contribution to a difﬁ  cult 
debate that has yet to provide a clear 
consensus: how and where should 
IPT be used, and what drugs should 
be used for it? The modellers need 
better data to reﬁ  ne their models and 
to make them more likely to produce 
realistic results. The debate will go on. 
Meanwhile, we should not delay in 
implementing other malaria control 
measures of proven effectiveness—
including deployment of highly 
efﬁ  cacious antimalarial combination 
drug treatment for symptomatic 
malaria in all malaria-endemic areas.   
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